Enhanced Blood Test for Colorectal Cancer Shows Improved Detection Rates
Recent updates to a blood test for colorectal cancer have significantly increased its ability to detect advanced precancerous lesions, according to a new study.
The updated blood test demonstrates an 80.4% sensitivity for colorectal cancer detection.
Detection of advanced precancerous lesions improved from 13.7% to 18.2% with the new version.
Experts suggest this advancement could shift the test's role from detection to prevention of cancer.
A recent study presented at the American College of Gastroenterology's annual meeting has revealed that enhancements to an FDA-approved blood test for colorectal cancer (CRC) have led to improved detection rates of advanced precancerous lesions (APLs). The findings, shared by Dr. Aasma Shaukat from NYU Grossman School of Medicine, indicate that the updated test could significantly reduce both the incidence and mortality rates of CRC at the population level.
Historically, colonoscopy and stool-based tests have been the primary methods for CRC screening as recommended by the American Cancer Society. However, the updated blood test offers an alternative for patients who are hesitant to undergo traditional screening methods. Dr. Shaukat emphasized that while colonoscopy remains the gold standard, the blood test is a viable option for those unwilling to participate in screening.
The study analyzed 9,131 samples from an average-risk population, including previously untested CRC samples and APL samples from the PREEMPT CRC trial. The updated SimpleScreen CRC test, which was introduced in 2025, showed a specificity of 90% and an overall sensitivity of 80.4% for CRC detection. Notably, the sensitivity for stage III CRC improved by 16.8%, while the sensitivity for detecting APL increased from 13.7% to 18.2%.
This advancement in detection capabilities is significant, as it suggests that the blood test could play a role in cancer prevention by identifying precancerous lesions. Dr. Michael Dougherty, a gastroenterologist, noted that these findings are groundbreaking, as they indicate a blood test's potential to detect precancerous conditions rather than just invasive cancers. He highlighted the importance of this shift in focus, which could lead to better patient outcomes.
Looking ahead, the implications of these findings are substantial for public health strategies in CRC screening. While the blood test presents a less invasive option, experts caution that it should not replace more accurate tests like colonoscopy or stool-based tests. The ongoing development of blood-based CRC tests will require careful consideration of their role in screening protocols to ensure they complement existing methods rather than detract from them. Future studies will be essential to further validate these findings and assess the long-term impact on CRC prevention and detection.
